Transcobalamin 2 variant associated with poststroke homocysteine modifies recurrent stroke risk

Neurology

Volumn 77, Issue 16, 2011, Pages 1543-1550

  Hsu, F C ^a   Sides, E G ^a   Mychaleckyj, J C ^b,c   Worrall, B B ^b,c   Elias, G A ^b   Liu, Y ^a   Chen, W M ^b,c   Coull, B M ^d   Toole, J F ^g   Rich, S S ^b,c   Furie, K L ^e,f   Sale, M M ^b,c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD UNIVERSITY   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); COBALAMIN; CYSTATHIONINE BETA SYNTHASE; CYSTATHIONINE GAMMA LYASE; FOLIC ACID; HOMOCYSTEINE; HOMOCYSTEINE METHYLTRANSFERASE; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; PYRIDOXINE; TRANSCOBALAMIN II;

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; SURVIVAL;

EID: 80051636872     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318233b1f9     Document Type: Article

References (40)

1. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Anderson CS. Long-term disability after first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989-1990. Stroke 2002;33:1034-1040. (Pubitemid 34293588)
2. Hankey GJ, Spiesser J, Hakimi Z, Carita P, Gabriel S. Time frame and predictors of recovery from disability following recurrent ischemic stroke. Neurology 2007;68: 202-205. (Pubitemid 46105738)
3. Toole JF. Vitamin intervention for stroke prevention. J Neurol Sci 2002;203-204:121-124. (Pubitemid 35287386)
4. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575. (Pubitemid 38500310)
5. Pettigrew LC, Bang H, Chambless LE, Howard VJ, Toole JF. Assessment of pre-and post-methionine load homocysteine for prediction of recurrent stroke and coronary artery disease in the Vitamin Intervention for Stroke Prevention Trial. Atherosclerosis 2008;200:345-349.
6. Sharma P, Senthilkumar RD, Brahmachari V, et al. Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids Health Dis 2006;5:1.
7. Wang J, Huff AM, Spence JD, Hegele RA. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration. Clin Genet 2004;65: 483-486. (Pubitemid 38786870)
8. Fredriksen A, Meyer K, Ueland PM, Vollset SE, Grotmol T, Schneede J. Large-scale population-based metabolic phenotyping of thirteen genetic polymorphisms related to one-carbon metabolism. Hum Mutat 2007;28:856-865. (Pubitemid 47579935)
9. Namour F, Olivier J, Abdelmouttaleb I, et al. Transcobalamin codon 259 polymorphism in HT-29 and Caco-2 cells and in Caucasians: relation to transcobalamin and homocysteine concentration in blood. Blood 2001;97:1092-1098. (Pubitemid 32154298)
10. Lievers KJ, Afman LA, Kluijtmans LA, et al. Polymorphisms in the transcobalamin gene: association with plasma homocysteine in healthy individuals and vascular disease patients. Clin Chem 2002;48:1383-1389. (Pubitemid 34925771)
11. Gunderson KL, Kruglyak S, Graige MS, et al. Decoding randomly ordered DNA arrays. Genome Res 2004;14: 870-877. (Pubitemid 38660504)
12. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265. (Pubitemid 40202029)
13. International HapMap Consortium. The International HapMap Project. Nature 2003;426:789-796.
14. Livak KJ, Marmaro J, Todd JA. Towards fully automated genome-wide polymorphism screening. Nat Genet 1995; 9:341-342.
15. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
16. Benjamini Y, Yekateuli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat 2001;29:1165-1188. (Pubitemid 33575263)
17. Bostom AG, Shemin D, Lapane KL, et al. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996;123:193-202. (Pubitemid 26175075)
18. Seetharam B, Bose S, Li N. Cellular import of cobalamin (vitamin B-12). J Nutr 1999;129:1761-1764. (Pubitemid 29468586)
19. Afman LA, Lievers KJ, Kluijtmans LA, Trijbels FJ, Blom HJ. Gene-gene interaction between the cystathionine-synthase 31 base pair variable number of tandem repeats and the methylenetetrahydrofolate reductase 677CT polymorphism on homocysteine levels and risk for neural tube defects. Mol Genet Metab 2003;78:211-215. (Pubitemid 36332022)
20. House AA, Eliasziw M, Cattran DC, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010;303:1603-1609.
21. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994;59:940-948. (Pubitemid 24112536)
22. Zeitlin A, Frishman WH, Chang CJ. The association of vitamin B 12 and folate blood levels with mortality and cardiovascular morbidity incidence in the old old: the Bronx aging study. Am J Ther 1997;4:275-281. (Pubitemid 27332890)
23. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-1781.
24. Kluijtmans LA, Boers GH, Stevens EM, et al. Defective cystathionine-synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient. J Clin Invest 1996;98:285-289. (Pubitemid 26255725)
25. Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine-synthase gene. Am J Hum Genet 1996;59:1262-1267. (Pubitemid 26394117)
26. De Stefano V, Dekou V, Nicaud V, et al. Linkage disequilibrium at the cystathionine synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine: the Ears II Group: European Atherosclerosis Research Study. Ann Hum Genet 1998;62:481-490. (Pubitemid 29237670)
27. Tsai MY, Yang F, Bignell M, Aras O, Hanson NQ. Relation between plasma homocysteine concentration, the 844ins68 variant of the cystathionine-synthase gene, and pyridoxal-5-phosphate concentration. Mol Genet Metab 1999;67:352-356. (Pubitemid 29406799)
28. Lievers KJ, Kluijtmans LA, Heil SG, et al. A 31 bp VNTR in the cystathionine-synthase (CBS) gene is associated with reduced CBS activity and elevated post-load homocysteine levels. Eur J Hum Genet 2001;9:583-589. (Pubitemid 32776373)
29. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-881.
30. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-113.
31. Harmon DL, Woodside JV, Yarnell JW, et al. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM 1996;89:571-577. (Pubitemid 26278868)
32. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9. (Pubitemid 26006560)
33. Malinow MR, Nieto FJ, Kruger WD, et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997;17:1157-1162. (Pubitemid 27260337)
34. Haapaniemi E, Helenius J, Soinne L, Syrjala M, Kaste M, Tatlisumak T. Serial measurements of plasma homocysteine levels in early and late phases of ischemic stroke. Eur J Neurol 2007;14:12-17. (Pubitemid 46088030)
35. Howard VJ, Sides EG, Newman GC, et al. Changes in plasma homocyst(e)ine in the acute phase after stroke. Stroke 2002;33:473-478. (Pubitemid 34123390)
36. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995;26:795-800.
37. Meiklejohn DJ, Vickers MA, Dijkhuisen R, Greaves M. Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke. Stroke 2001;32:57-62. (Pubitemid 32063824)
38. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077-1080. (Pubitemid 29230859)
39. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236. (Pubitemid 27310438)
40. Ntaios GC, Savopoulos CG, Chatzinikolaou AC, Kaiafa GD, Hatzitolios A. Vitamins and stroke: the homocysteine hypothesis still in doubt. Neurologist 2008;14:2-4.